The Center for Translational and Policy Research on Personalized Medicine

Basic Research

Clinical Research

Policy ResearchAdoption

Outcomes

Who has access to interventions?

How do we trade-off between

preferences, costs, and benefits?

…and we must answer these questions….

Adoption

What evidence do decisionmakers

need?

How to translate knowledge to real world?

How can we consider diversity?

To improve patient outcomes, new technologies must move through the Translational Continuum….

We Can’t Address Issues Alone

Patient Advocates

Aca-demic Groups

Gov-ernment Groups

Professional Organiza-tions

Health Plans and Payers

Industry & Ven-

ture Capital Labs

Pharmacy Benefit Managers

TRANSPERS is Integrated Across

Stakeholders

TRANSPERS Uses Toolbox of Social Science Approaches & Methods…

…To Understand Health Policy Issues…

…In the Brave New World of New Technologies & Personalized Medicine

Personalized Medicine is Here Now – and is the Wave of the Future

But a Deluge of Information

1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 20110

100200300400500600700800900

10001100120013001400150016001700180019002000210022002300240025002600

www.GeneTests.org. Univ of WA

Number of Diseases for Which Genetic Tests are Available Rapidly Increasing

Cost of Whole Genome Sequencing is Falling

Now the Big Challenge: Having It All

New TRANSPERS StudyBenefit-Risk Tradeoffs for Whole Genome Sequencing

• How do patients and providers value information provided?

• Will sequencing will be covered by payers?• Will value outweigh costs?

– PI: Kathryn A. Phillips UCSF, 2013-2017, $2.4M– With Harvard Medical School

For More Information

http://transpers.ucsf.edu

TRANSPERSinfo@ucsf.edu

PhillipsK@pharmacy.ucsf.edu